Form 4: Precigen CFO Harry Thomasian Jr. Receives Equity Grant

Precigen CFO Harry Thomasian Jr. was granted 399,000 stock options and 120,000 restricted stock units on April 20, 2026.

Summary

• Harry Thomasian Jr., Chief Financial Officer of Precigen, Inc., received a new equity compensation package.
• The grant consists of 399,000 stock options with an exercise price of $4.11.
• The grant also includes 120,000 restricted stock units (RSUs).
• Both the options and RSUs follow a multi-year vesting schedule beginning in May 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value.
• The multi-year vesting schedule (four years) encourages executive retention.

Negatives

• The issuance of new equity awards results in potential future dilution for existing shareholders.

Risks

• The value of the granted equity is subject to market volatility and the future performance of Precigen common stock.

Future Outlook

The equity grants are subject to a vesting schedule that spans four years, indicating a long-term commitment to the company's growth strategy.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives are standard practice in the biotechnology sector to incentivize leadership during long-term R&D and clinical trial cycles.

Comparison to Industry Standards

• The use of a four-year vesting schedule is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The mix of stock options and RSUs is a common approach to balance performance-based incentives with retention-focused equity.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise and vesting of these equity instruments.

Next Steps

• Vesting of 25% of the options and RSUs on May 23, 2027.

Key Dates

Keywords

Precigen, PGEN, Form 4, Executive Compensation, Stock Options, Restricted Stock Units, Insider Transaction